Advertisement

Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration

      Purpose

      To compare time to retreatment and visual function between patients with treatment-naïve neovascular age-related macular degeneration (AMD) treated with either intravitreal ranibizumab (IVR) or intravitreal aflibercept (IVA) in routine clinical practice.

      Design

      Retrospective, interventional comparative case series.

      Participants

      A total of 200 eyes of 197 patients with neovascular AMD.

      Methods

      A total of 99 patients in the IVR group and 101 patients in the IVA group who met the inclusion criteria with 12 months of follow-up were included in the present study. All patients received 3 consecutive monthly injections of 0.5 mg/0.05 mL ranibizumab or 2.0 mg/0.05 mL aflibercept as loading doses. Retreatment was allowed if evidence of clinical deterioration or the presence of intraretinal edema or subretinal fluid on spectral-domain optical coherence tomography examination performed at the 1-month follow-up was noted. The time to retreatment after the third injection during the loading phase to the first recurrence during the maintenance phase was compared between treatments using the Kaplan-Meier analysis. Functional and anatomic outcomes were also compared between the IVR and IVA groups.

      Results

      The median time to retreatment after the last induction dose was 5 months in both groups. The proportion of IVR patients who required injection retreatment was not significantly higher than that of IVA patients (67.7% and 63.4%, respectively, at the 12-month follow up; log-rank test, P = .554). In both groups, significant improvements in postoperative best-corrected visual acuity (BCVA) compared with preoperative visual acuity was observed over the 12-month follow-up period (P < .05 for both). Central foveal thickness (CFT) decreased from the baseline values in both groups during the follow-up period (P < .001 for both). Although there was a trend toward greater BCVA improvements in the IVA group, no significant differences in BCVA or CFT were observed between the treatment groups.

      Conclusions

      Both IVR and IVA were well tolerated and demonstrated efficacy in improving the visual acuity in treatment-naïve patients with AMD. Despite a trend toward greater BCVA improvements in the IVA group, a similar injection burden was observed following the loading phases of both ranibizumab and aflibercept.
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to American Journal of Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rosenfeld P.J.
        • Brown D.M.
        • Heier J.S.
        • et al.
        Ranibizumab for neovascular age-related macular degeneration.
        N Engl J Med. 2006; 355: 1419-1431
        • Heier J.S.
        • Brown D.M.
        • Chong V.
        • et al.
        Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
        Ophthalmology. 2012; 119: 2537-2548
        • Gragoudas E.S.
        • Adamis A.P.
        • Cunningham E.T.
        • et al.
        Group VISiONCT. Pegaptanib for neovascular age-related macular degeneration.
        N Engl J Med. 2004; 351: 2805-2816
        • Kaiser P.K.
        Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration.
        Core Evid. 2008; 2: 273-294
        • Brown D.M.
        • Kaiser P.K.
        • Michels M.
        • et al.
        Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
        N Engl J Med. 2006; 355: 1432-1444
        • Lalwani G.A.
        • Rosenfeld P.J.
        • Fung A.E.
        • et al.
        A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
        Am J Ophthalmol. 2009; 148: 43-58
        • Schmidt-Erfurth U.
        • Kaiser P.K.
        • Korobelnik J.F.
        • et al.
        Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
        Ophthalmology. 2014; 121: 193-201
        • Maruko I.
        • Iida T.
        • Saito M.
        • Nagayama D.
        • Saito K.
        Clinical characteristics of exudative age-related macular degeneration in Japanese patients.
        Am J Ophthalmol. 2007; 144: 15-22
        • Dirani A.
        • Ambresin A.
        • Marchionno L.
        • Decugis D.
        • Mantel I.
        Factors influencing the treatment response of pigment epithelium detachment in age-related macular degeneration.
        Am J Ophthalmol. 2015; 160: 732-738
        • Cho H.J.
        • Kim K.M.
        • Kim H.S.
        • et al.
        Intravitreal aflibercept and ranibizumab injections for polypoidal choroidal vasculopathy.
        Am J Ophthalmol. 2016; 165: 1-6
        • Yamamoto A.
        • Okada A.A.
        • Kano M.
        • et al.
        One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy.
        Ophthalmology. 2015; 122: 1866-1872
        • Engelbert M.
        • Zweifel S.A.
        • Freund K.B.
        “Treat and extend” dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation.
        Retina. 2009; 29: 1424-1431
        • Engelbert M.
        • Zweifel S.A.
        • Freund K.B.
        Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified “treat and extend” dosing regimen of intravitreal antivascular endothelial growth factor therapy.
        Retina. 2010; 30: 1368-1375
        • Holash J.
        • Davis S.
        • Papadopoulos N.
        • et al.
        VEGF-Trap: a VEGF blocker with potent antitumor effects.
        Proc Natl Acad Sci U S A. 2002; 99: 11393-11398
        • Stewart M.W.
        • Rosenfeld P.J.
        • Penha F.M.
        • et al.
        Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
        Retina. 2012; 32: 434-457
        • Niwa Y.
        • Kakinoki M.
        • Sawada T.
        • Wang X.
        • Ohji M.
        Ranibizumab and aflibercept: intraocular pharmacokinetics and their effects on aqueous VEGF level in vitrectomized and nonvitrectomized macaque eyes.
        Invest Ophthalmol Vis Sci. 2015; 56: 6501-6505
        • Kuroda Y.
        • Yamashiro K.
        • Miyake M.
        • et al.
        Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study.
        Ophthalmology. 2015; 122: 2303-2310
        • Rofagha S.
        • Bhisitkul R.B.
        • Boyer D.S.
        • Sadda S.R.
        • Zhang K.
        • SEVEN-UP Study Group
        Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).
        Ophthalmology. 2013; 120: 2292-2299
        • Grunwald J.E.
        • Daniel E.
        • Huang J.
        • et al.
        Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials.
        Ophthalmology. 2014; 121: 150-161
        • Ying G.S.
        • Huang J.
        • Maguire M.G.
        • et al.
        Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.
        Ophthalmology. 2013; 120: 122-129
        • Grunwald J.E.
        • Pistilli M.
        • Ying G.S.
        • et al.
        Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials.
        Ophthalmology. 2015; 122: 809-816
        • Julien S.
        • Biesemeier A.
        • Taubitz T.
        • Schraermeyer U.
        Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes.
        Br J Ophthalmol. 2014; 98: 813-825

      Linked Article